vs
CANTALOUPE, INC.（CTLP）与MESA LABORATORIES INC（MLAB）财务数据对比。点击上方公司名可切换其他公司
CANTALOUPE, INC.的季度营收约是MESA LABORATORIES INC的1.2倍（$78.7M vs $65.1M），MESA LABORATORIES INC净利率更高（5.6% vs -0.1%，领先5.7%），CANTALOUPE, INC.同比增速更快（6.8% vs 3.6%），MESA LABORATORIES INC自由现金流更多（$18.0M vs $-614.0K），过去两年CANTALOUPE, INC.的营收复合增速更高（7.7% vs 5.1%）
坎塔卢波（原美国技术公司）是一家美国科技企业，核心业务为ePort无现金支付受理技术，依托持专利的PCI合规ePort Connect服务开展运营。该服务可通过无线方式为消费者提供信用卡、借记卡以及Apple Pay、Google Pay等NFC钱包支付选项，同时为运营商提供遥测与机器间通信服务，ePort技术主要应用于...
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
CTLP vs MLAB — 直观对比
营收规模更大
CTLP
是对方的1.2倍
$65.1M
营收增速更快
CTLP
高出3.1%
3.6%
净利率更高
MLAB
高出5.7%
-0.1%
自由现金流更多
MLAB
多$18.6M
$-614.0K
两年增速更快
CTLP
近两年复合增速
5.1%
损益表 — Q2 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $78.7M | $65.1M |
| 净利润 | $-70.0K | $3.6M |
| 毛利率 | — | 64.2% |
| 营业利润率 | 2.0% | 12.2% |
| 净利率 | -0.1% | 5.6% |
| 营收同比 | 6.8% | 3.6% |
| 净利润同比 | -101.4% | 316.6% |
| 每股收益（稀释后） | $0.00 | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTLPMLAB
| Q4 25 | $78.7M | $65.1M | ||
| Q3 25 | $80.9M | $60.7M | ||
| Q2 25 | $82.6M | $59.5M | ||
| Q1 25 | $75.4M | $62.1M | ||
| Q4 24 | $73.7M | $62.8M | ||
| Q3 24 | $70.8M | $57.8M | ||
| Q2 24 | $72.7M | $58.2M | ||
| Q1 24 | $67.9M | $58.9M |
净利润CTLPMLAB
| Q4 25 | $-70.0K | $3.6M | ||
| Q3 25 | $-919.0K | $2.5M | ||
| Q2 25 | $6.8M | $4.7M | ||
| Q1 25 | $49.2M | $-7.1M | ||
| Q4 24 | $5.0M | $-1.7M | ||
| Q3 24 | $3.6M | $3.4M | ||
| Q2 24 | $2.2M | $3.4M | ||
| Q1 24 | $4.7M | $-254.6M |
毛利率CTLPMLAB
| Q4 25 | — | 64.2% | ||
| Q3 25 | — | 61.5% | ||
| Q2 25 | — | 62.0% | ||
| Q1 25 | — | 61.8% | ||
| Q4 24 | — | 63.3% | ||
| Q3 24 | — | 61.3% | ||
| Q2 24 | — | 64.0% | ||
| Q1 24 | 39.6% | 62.1% |
营业利润率CTLPMLAB
| Q4 25 | 2.0% | 12.2% | ||
| Q3 25 | 2.0% | 7.8% | ||
| Q2 25 | 6.3% | 5.1% | ||
| Q1 25 | 9.1% | 2.4% | ||
| Q4 24 | 8.4% | 9.2% | ||
| Q3 24 | 5.8% | 6.1% | ||
| Q2 24 | 4.9% | 9.6% | ||
| Q1 24 | 6.3% | -460.6% |
净利率CTLPMLAB
| Q4 25 | -0.1% | 5.6% | ||
| Q3 25 | -1.1% | 4.1% | ||
| Q2 25 | 8.3% | 8.0% | ||
| Q1 25 | 65.2% | -11.4% | ||
| Q4 24 | 6.7% | -2.7% | ||
| Q3 24 | 5.0% | 5.9% | ||
| Q2 24 | 3.0% | 5.8% | ||
| Q1 24 | 6.9% | -432.2% |
每股收益（稀释后）CTLPMLAB
| Q4 25 | $0.00 | $0.65 | ||
| Q3 25 | $-0.02 | $0.45 | ||
| Q2 25 | $0.10 | $0.85 | ||
| Q1 25 | $0.65 | $-1.30 | ||
| Q4 24 | $0.07 | $-0.31 | ||
| Q3 24 | $0.04 | $0.63 | ||
| Q2 24 | $0.03 | $0.62 | ||
| Q1 24 | $0.06 | $-47.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $53.0M | $29.0M |
| 总债务越低越好 | $37.7M | $68.4M |
| 股东权益账面价值 | $252.5M | $186.7M |
| 总资产 | $381.9M | $434.8M |
| 负债/权益比越低杠杆越低 | 0.15× | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资CTLPMLAB
| Q4 25 | $53.0M | $29.0M | ||
| Q3 25 | $55.0M | $20.4M | ||
| Q2 25 | $51.1M | $21.3M | ||
| Q1 25 | $46.3M | $27.3M | ||
| Q4 24 | $27.7M | $27.3M | ||
| Q3 24 | $33.1M | $24.3M | ||
| Q2 24 | $58.9M | $28.5M | ||
| Q1 24 | $50.2M | $28.2M |
总债务CTLPMLAB
| Q4 25 | $37.7M | $68.4M | ||
| Q3 25 | $38.3M | $69.4M | ||
| Q2 25 | $38.7M | $70.3M | ||
| Q1 25 | $39.2M | $71.3M | ||
| Q4 24 | $37.0M | $72.2M | ||
| Q3 24 | $37.3M | $73.1M | ||
| Q2 24 | $37.5M | $74.1M | ||
| Q1 24 | $38.1M | — |
股东权益CTLPMLAB
| Q4 25 | $252.5M | $186.7M | ||
| Q3 25 | $251.8M | $178.5M | ||
| Q2 25 | $251.0M | $172.5M | ||
| Q1 25 | $240.7M | $159.8M | ||
| Q4 24 | $190.1M | $155.2M | ||
| Q3 24 | $186.2M | $161.5M | ||
| Q2 24 | $181.7M | $150.7M | ||
| Q1 24 | $178.8M | $145.4M |
总资产CTLPMLAB
| Q4 25 | $381.9M | $434.8M | ||
| Q3 25 | $389.5M | $430.4M | ||
| Q2 25 | $381.9M | $435.7M | ||
| Q1 25 | $370.5M | $433.3M | ||
| Q4 24 | $303.0M | $433.3M | ||
| Q3 24 | $312.1M | $454.1M | ||
| Q2 24 | $335.6M | $440.4M | ||
| Q1 24 | $319.9M | $446.8M |
负债/权益比CTLPMLAB
| Q4 25 | 0.15× | 0.37× | ||
| Q3 25 | 0.15× | 0.39× | ||
| Q2 25 | 0.15× | 0.41× | ||
| Q1 25 | 0.16× | 0.45× | ||
| Q4 24 | 0.19× | 0.47× | ||
| Q3 24 | 0.20× | 0.45× | ||
| Q2 24 | 0.21× | 0.49× | ||
| Q1 24 | 0.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.1M | $18.8M |
| 自由现金流经营现金流 - 资本支出 | $-614.0K | $18.0M |
| 自由现金流率自由现金流/营收 | -0.8% | 27.7% |
| 资本支出强度资本支出/营收 | 4.8% | 1.1% |
| 现金转化率经营现金流/净利润 | — | 5.17× |
| 过去12个月自由现金流最近4个季度 | $25.8M | $37.9M |
8季度趋势，按日历期对齐
经营现金流CTLPMLAB
| Q4 25 | $3.1M | $18.8M | ||
| Q3 25 | $7.0M | $8.2M | ||
| Q2 25 | $9.4M | $1.9M | ||
| Q1 25 | $22.4M | $12.7M | ||
| Q4 24 | $522.0K | $18.1M | ||
| Q3 24 | $-12.0M | $5.3M | ||
| Q2 24 | $14.3M | $10.7M | ||
| Q1 24 | $14.7M | $12.9M |
自由现金流CTLPMLAB
| Q4 25 | $-614.0K | $18.0M | ||
| Q3 25 | $3.5M | $7.1M | ||
| Q2 25 | $4.3M | $884.0K | ||
| Q1 25 | $18.6M | $11.9M | ||
| Q4 24 | $-3.8M | $17.3M | ||
| Q3 24 | $-15.8M | $3.5M | ||
| Q2 24 | $8.5M | $9.9M | ||
| Q1 24 | $11.4M | $12.3M |
自由现金流率CTLPMLAB
| Q4 25 | -0.8% | 27.7% | ||
| Q3 25 | 4.4% | 11.7% | ||
| Q2 25 | 5.3% | 1.5% | ||
| Q1 25 | 24.6% | 19.2% | ||
| Q4 24 | -5.1% | 27.6% | ||
| Q3 24 | -22.3% | 6.0% | ||
| Q2 24 | 11.7% | 16.9% | ||
| Q1 24 | 16.9% | 21.0% |
资本支出强度CTLPMLAB
| Q4 25 | 4.8% | 1.1% | ||
| Q3 25 | 4.2% | 1.8% | ||
| Q2 25 | 6.2% | 1.7% | ||
| Q1 25 | 5.1% | 1.2% | ||
| Q4 24 | 5.8% | 1.3% | ||
| Q3 24 | 5.4% | 3.1% | ||
| Q2 24 | 7.9% | 1.5% | ||
| Q1 24 | 4.8% | 0.9% |
现金转化率CTLPMLAB
| Q4 25 | — | 5.17× | ||
| Q3 25 | — | 3.32× | ||
| Q2 25 | 1.38× | 0.40× | ||
| Q1 25 | 0.46× | — | ||
| Q4 24 | 0.10× | — | ||
| Q3 24 | -3.36× | 1.54× | ||
| Q2 24 | 6.47× | 3.17× | ||
| Q1 24 | 3.16× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTLP
| Transaction Processing | $47.9M | 61% |
| Subscription Revenue | $21.8M | 28% |
| Products | $9.0M | 11% |
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
